Current Medical Research and Opinion最新文献

{"title":"To create an algorithm assessing the risk of ovarian cancer in primary care using generalized additive² model (GA²M) and traditional methods.","authors":"Francesco Lapi, Ettore Marconi, Lorenzo Nuti, Iacopo Cricelli, Marco Gorini, Stefania Marcoli, Alessandro Rossi, Claudio Cricelli","doi":"10.1080/03007995.2025.2534467","DOIUrl":"10.1080/03007995.2025.2534467","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to evaluate models designed to support the exploration and early detection of potential Ovarian Cancer (OC) using either Machine Learning (ML) techniques or traditional methodologies, using primary care data. This evaluation aimed to facilitate appropriate and timely referrals to specialists.</p><p><strong>Methods: </strong>The Health Search database, containing healthcare records of 1 million adults, was used to predict OC cases among patients aged 18+ without prior OC diagnosis from 1 January 2002, to June 2021. GA²M, logistic regression, and Gradient Boosting Machines (GBM) were trained using 20 determinants, with prediction performance assessed via Area Under Curve (AUC) and Average Precision (AP). A traditional cohort design with nested case-control analysis developed a prediction algorithm using the same determinants, evaluating explained variation, AUC, and slope calibration.</p><p><strong>Results: </strong>Comparing the predictive performances of the three models, the AUC and AP for GA²M showed the highest values, which were equal to 69.1 and 0.7%, respectively. The GA²M-based algorithm outperformed the algorithm obtained with the traditional approach, which showed an overestimation of risk, as confirmed by a calibration slope of 1.75 along with an AUC of 55%.</p><p><strong>Conclusions: </strong>The GA²M-based algorithm outperformed the light GBM, logistic regression, and traditional models in predicting OC. This suggests that ML techniques are preferable for algorithms involving complex predictor interplays in assessing rare event risks, such as OC. The GA²M-based algorithm is reliable for OC prediction in primary care compared to traditional methods, indicating its potential for use in decision support systems for general practitioners.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"939-948"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new strategy for the selection of patients with hip osteoarthritis to avoid inappropriate total hip replacement based on imaging and clinical characteristics.","authors":"Kazuo Hayashi, Yves Henrotin, Toshiharu Tsunoda, Shoji Tokunaga","doi":"10.1080/03007995.2025.2521097","DOIUrl":"10.1080/03007995.2025.2521097","url":null,"abstract":"<p><strong>Background: </strong>Total hip replacement (THR) is extremely common and generally results in excellent patient satisfaction. However, 36% of patients with hip osteoarthritis who undergo THR reportedly experience long-term postoperative pain. Furthermore, only 20% of patients attempt exercise before surgery, despite the recommendation for 3-6 months of conservative treatment before surgery. Despite these facts, the number of THRs performed annually is currently increasing.</p><p><strong>Objectives: </strong>To propose and discuss a new strategy based on clinical and radiological characteristics for selecting candidates for Pericapsular Soft Tissue and Pelvic Realignment (PSTP-R) therapies to avoid inappropriate THR.</p><p><strong>Methods: </strong>The PubMed electronic database was searched to identify publications reporting data from clinical studies on the diagnosis and treatment of osteoarthritis in humans published between 1995 and 2023. This narrative review summarizes the findings of these previous studies.</p><p><strong>Results: </strong>A previous study reported that PSTP-R therapy comprising pelvic realignment, muscle strengthening, and stretching was effective for patients with a Harris Hip Score (HHS) below 60 points, even those with complete loss of cartilage on radiography. A post hoc study showed that the risk of discontinuation of PSTP-R therapy increased with increasing frequency of pain in the buttock at baseline. Cartilage loss was not a risk factor for withdrawal from PSTP-R therapy.</p><p><strong>Conclusion: </strong>Patients should be better informed regarding the benefits of THR and the possibility of persistent postoperative pain. If the patient has complete loss of cartilage on radiography but no buttock pain, PSTP-R therapy might improve their pain and avoid THR.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"995-1006"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world clinical outcomes of patients with moderate-to-severe rheumatoid arthritis initiating upadacitinib in the United Kingdom: final analysis from a prospective observational cohort study (ENDEAVOUR).","authors":"James Taylor, Srinivasan Srirangan, Marwan Bukhari, Syed Bilgrami, Muhammad K Nisar, Stephen McDonald, Nicola Goodson, Andrew Allard, Alison Kinder, Michael Green, Laura Hunt, Sabrina Raizada, Bruce Kirkham, Eleri Thomas, Rachel Horsfall, Terri-Leigh Niblock, Victoria Burton, James Galloway","doi":"10.1080/03007995.2025.2515280","DOIUrl":"10.1080/03007995.2025.2515280","url":null,"abstract":"<p><strong>Objective: </strong>Upadacitinib is recommended by National Institute for Health and Care Excellence in the UK in adults with moderate-to-severe rheumatoid arthritis (RA). This observational study assessed real-world clinical outcomes and patient-reported outcomes (PROs) in patients receiving upadacitinib for 6 months in the UK.</p><p><strong>Methods: </strong>Patients from 14 centres in whom the decision to initiate upadacitinib had already been made were enrolled. Baseline data were retrospectively collected from patient records. Clinician-reported data were collected at routine clinic visits 3 and 6 months after upadacitinib initiation. Patient-reported data were collected directly from patients using an app (electronic PROs, ePROs). The primary end-point was proportion of patients achieving clinical remission (DAS28 CRP <2.6) after 6 months of upadacitinib.</p><p><strong>Results: </strong>Data are available for 63 patients at all three datapoints and for 53 patients for the primary end-point. At 6 months, 40% (21/53) of patients achieved clinical remission and 21% (11/53) achieved low disease activity. Response was seen at 3 months for all efficacy end-points. ePROs allowed the capture of early patient-reported data which demonstrated clinically important improvements in pain and fatigue within 10 days and other PROs within 2 months. Improvements were also seen in metrics of activity, work and quality of life (QOL).</p><p><strong>Conclusion: </strong>Patients in ENDEAVOUR showed similar early effectiveness with upadacitinib to that observed in clinical trials. Use of ePROs demonstrated rapid onset of action and meaningful improvements in QOL providing a potential opportunity to reduce outpatient visits for early responders, thus reducing the burden on rheumatology services.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1097-1109"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical site infections with multi-drug resistant organisms in patients undergoing neurosurgery: a retrospective comparative cohort study from Turkey.","authors":"Yasemin Nadir, Pinar Kiran, Hale Turan Ozden, Sabri Atalay","doi":"10.1080/03007995.2025.2522805","DOIUrl":"10.1080/03007995.2025.2522805","url":null,"abstract":"<p><strong>Background: </strong>Multidrug-resistant organisms (MDROs) are a growing global health threat, contributing to higher morbidity and mortality, particularly for surgical site infections (SSIs). This study investigates the risk factors and outcomes of SSIs caused by MDROs in patients undergoing neurosurgery.</p><p><strong>Methods: </strong>This study was a retrospective comparative study which included 202 patients that had SSIs after neurosurgical procedures between 2014 and 2024 in Turkey. Patients were divided into two groups according to results of wound culture: MDRO and non-MDRO groups. Binary logistic regression was used to identify independent risk factors for MDRO-related SSIs.</p><p><strong>Results: </strong>The MDRO group (<i>n</i> = 60) had significantly higher all-cause mortality (28.3% vs. 8.5%, <i>p</i> <0.01), ICU admission (81.7% vs. 57%, <i>p</i> = 0.01), and longer hospital stays (30 days vs. 24 days, <i>p</i> = 0.04) compared to the non-MDRO group (<i>n</i> = 142). Emergency surgeries, American Society of Anesthesiologists (ASA) grade ≥3, corticosteroid use and organ/space SSIs were identified as significant risk factors. Logistic regression analysis revealed that only organ/space SSIs were independently associated with MDRO-related SSIs (<i>p</i> <0.01).</p><p><strong>Conclusion: </strong>This study highlights the significance of MDRO-related SSIs in neurosurgery by demonstrating worse clinical outcomes, including higher mortality, prolonged hospital stays, and increased ICU admission rates. By identifying key risk factors, it contributes to the management of SSIs and supports the development of targeted prevention and control strategies in neurosurgical settings. These findings underscore the need for enhanced infection control measures and may inform future clinical guidelines and research aimed at reducing the burden of MDRO infections in neurosurgical patients.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1111-1119"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of the relationship between the inclusion of industry authors and the impact and perception of peer-reviewed scientific publications.","authors":"Sanchaita Sriwal Sonar, Emma Raderschadt, Shivangi Gupta, Stefan Courtney, Rachana Patel","doi":"10.1080/03007995.2025.2527673","DOIUrl":"10.1080/03007995.2025.2527673","url":null,"abstract":"<p><strong>Objective: </strong>To assess whether pharmaceutical industry authorship affects the impact and perceived credibility of clinical publications.</p><p><strong>Methods: </strong>A PubMed search for clinical trials in four therapy areas (oncology, cardiometabolism, central nervous system and inflammation), published in peer-reviewed journals between 2018 and 2023, was performed. Industry authors were identified. Publication impact (total citations and X interactions) was analyzed for each paper. A multinational survey of 180 healthcare professionals assessed whether industry authorship affects perception of publications.</p><p><strong>Results: </strong>A weak but significant negative correlation was demonstrated between the percentage of industry authors and academic citations and X interactions (r = -0.10 and r = -0.13, respectively; both <i>p</i> < 0.0001), regardless of journal impact factor or total author number. Papers with ≥50% or lead/last authors from industry had significantly lower citations and X interactions. In the survey, 57% of respondents thought author affiliation and 24% thought industry affiliation were important factors affecting publication credibility. Over half of respondents thought publication credibility decreased due to high numbers (56%) or a majority (61%) of industry authors, and an industry author as lead/last author (57%). 68% associated high numbers of industry authors with a potential for bias.</p><p><strong>Conclusion: </strong>These analyses show that industry authorship influences the credibility and impact of scientific publications. It is essential to raise awareness of the pharmaceutical industry's commitment to good publication practices, which ensures authorship is based on merit and genuine contributions. Future research should focus on understanding and addressing how authorship dynamics shape the perception and trustworthiness of scientific work, ensuring a balance that fosters both innovation and public confidence.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1065-1074"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tobacco smoking and sarcoidosis revisited-Evidence, mechanisms, and clinical implications: a narrative review.","authors":"Nadia Sweis, Arnaud Dominati, Supritha Prasad, Fatima Alnaimat, Mina Alawqati, Israel Rubinstein, Rachel Caskey","doi":"10.1080/03007995.2025.2495852","DOIUrl":"10.1080/03007995.2025.2495852","url":null,"abstract":"<p><p>Sarcoidosis is a multisystem inflammatory disease with unclear etiology, influenced by genetic predisposition and environmental exposures. Smoking has been widely studied for its potential role in sarcoidosis, with conflicting evidence regarding its impact on disease risk, severity, and treatment response. While some epidemiologic studies suggest that smoking is associated with a lower risk of sarcoidosis, others highlight variations based on geography, ethnicity, and smoking history. Assessing the effects of smoking is particularly challenging because of the complex composition of tobacco smoke, which contains thousands of chemicals with diverse biologic effects. Nicotine, a major component of tobacco, has demonstrated both pro- and anti-inflammatory properties, further complicating its role in sarcoidosis. This narrative review explored the complex relationship between smoking and sarcoidosis by examining smoking's effects on immune modulation, disease presentation and prognosis, and response to immunosuppressive therapy. By summarizing current evidence, this paper aimed to clarify the impact of smoking and nicotine on sarcoidosis and identify key areas for future research, particularly in understanding the mechanisms underlying smoking-related immune modulation and treatment outcomes.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"901-916"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GPP 2022: perspectives, sentiments, and feedback from the publications community.","authors":"Raghuraj Puthige, Dikran Toroser, Anisha Mehra, Dhanya Mukundan, Anupama Kapadia","doi":"10.1080/03007995.2025.2503975","DOIUrl":"10.1080/03007995.2025.2503975","url":null,"abstract":"<p><strong>Objective: </strong>To identify the impact and integration of GPP 2022 guidelines on the work processes of publications developed in pharmaceutical, publishing, agency, and academic circles.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted for 3 weeks from March 1-22, 2024 among medical publication professionals and healthcare researchers. The survey included questions that have been traditionally challenging in publication workstreams and were disseminated through major medical communications networking groups. The survey results were summarized as a percentage for each answer rounded to one decimal place.</p><p><strong>Results: </strong>A total of 100 participants responded to the survey among whom 67.0% were familiar with the GPP 2022 guidelines. To mitigate potential misinterpretation risks, we considered only respondents familiar with the guidelines. More than half of the respondents (55.7%) felt that GPP 2022 was effective in addressing ethical considerations; 34.4% respondents agreed that GPP 2022 provided useful guidance on best practices in transparency and data-sharing. Most survey respondents (54.5%) agreed that the authorship and contributorship criteria were clear in GPP 2022. 37.3% of the survey respondents were familiar with publication extenders and felt that extenders added value to the dissemination of research findings; 39.2% were aware of plain-language summaries and 82.4% viewed them as vital for widespread research accessibility.</p><p><strong>Conclusion: </strong>The survey suggests a need to improve awareness and support for implementing transparency initiatives that aid in the publication process. Furthermore, although most respondents were aware of publication extenders, there was a need for clarification and harmonization of guidelines on publication extenders.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"879-885"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of appetite loss and related factors in older patients with cancer: validation of the cancer appetite and symptom questionnaire (CASQ) in Turkish patients.","authors":"Digdem Dogan Akagunduz, Hilal Şahin, Ferhan Elmalı, Baran Akagunduz","doi":"10.1080/03007995.2025.2502669","DOIUrl":"10.1080/03007995.2025.2502669","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to validate the Cancer Appetite and Symptom Questionnaire (CASQ) for Turkish older cancer patients and identify factors influencing appetite loss and related symptoms. The research question focused on whether the CASQ is a reliable tool for assessing appetite-related symptoms and determining associated risk factors in this population.</p><p><strong>Methods: </strong>A total of 240 cancer patients aged ≥70 years were recruited from a Turkish oncology clinic. Demographic, cancer-related, nutritional, functional, and psychological data were collected. Appetite was assessed using the CASQ and Simplified Nutritional Appetite Questionnaire (SNAQ). Structural validity, reliability, and diagnostic performance were evaluated through exploratory factor analysis (EFA) and confirmatory factor analysis (CFA). Logistic regression was performed to identify factors associated with appetite loss.</p><p><strong>Results: </strong>The CASQ demonstrated high reliability and validity, with a Cronbach's alpha of 0.971 and Kaiser-Meyer-Olkin (KMO) of 0.907. EFA and CFA supported a single-factor structure. A CASQ cutoff score of 32 showed high diagnostic accuracy (AUC: 0.971) with 88.9% sensitivity. Appetite loss was reported in 53.7% of patients and was significantly associated with stage IV cancer (OR: 10.112, <i>p</i> < .001), chemotherapy (OR: 2.960, <i>p</i> = .016), severe pain (OR: 3.089, <i>p</i> = .003), malnutrition (OR: 4.459, <i>p</i> = .033), polypharmacy (OR: 2.213, <i>p</i> = .040), and poor performance status (OR: 5.245, <i>p</i> = .017).</p><p><strong>Conclusions: </strong>The CASQ is a validated, reliable tool for assessing appetite-related symptoms in Turkish older cancer patients. Findings underscore the need for integrated nutritional and psychological care. Future research should develop targeted interventions to mitigate appetite loss and its impact on quality of life in this population.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"789-797"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional improvement as a treatment goal in major depressive disorder: a narrative review of the evidence for vortioxetine.","authors":"Pratap Chokka, Lene Hammer-Helmich, Simon Nitschky Schmidt, Martine Hubert, Elin H Reines, Iria Grande","doi":"10.1080/03007995.2025.2503976","DOIUrl":"10.1080/03007995.2025.2503976","url":null,"abstract":"<p><p>This narrative review used manufacturer-sponsored vortioxetine clinical trial database (doses of 5-20 mg) to evaluate the effect of vortioxetine treatment on short- and long- term functional outcomes in major depressive disorder (MDD), in both the clinical trial setting and in routine practice. The Sheehan Disability Scale (SDS) was the most used functional scale and, based on this measure, short-term, placebo-controlled studies demonstrated significant improvements with vortioxetine 10 mg (reductions ranged from -0.92 to -2.10 points vs placebo after 6-8 weeks treatment) and 20 mg (reductions ranged from -0.88 to -3.92 vs placebo). Of note, the acute beneficial effects of vortioxetine on functionality were seen in patients with severe baseline depressive symptoms as well as those with significant anxiety. Long-term open-label extension studies further showed that maintenance treatment was associated with continued functional improvements over one year (reaching an average reduction of -6.2 SDS points from baseline) that were correlated with continued improvements in residual symptoms. Evidence from real-world studies, using multiple functional outcomes, further demonstrated generalizability to routine practice where patients are living with multiple comorbidities previously excluded from the randomized controlled trials. Taken overall, the findings from several head-to-head studies indicated a functional advantage of vortioxetine compared with other classes of antidepressants and demonstrated the effectiveness of vortioxetine as first-line treatment while also confirming its effectiveness in improving functional outcomes when given later in the treatment journey. In summary, vortioxetine is an effective treatment option for improving functional outcomes in people living with MDD.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"855-866"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported real-world experience of risankizumab on-body device (OBD) for the treatment of Crohn's disease in the UK (COMMODUS).","authors":"Adil Jaulim, Anna Stanton, Sherill Tripoli, Ana Ibarra, David Young, Mary Doona, Fraser Cummings, Ally Speight, Shahida Din, James O Lindsay, Rachel Horsfall, Mark Sephton, Mark A Samaan","doi":"10.1080/03007995.2025.2506808","DOIUrl":"10.1080/03007995.2025.2506808","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate real-world patient-reported experience with subcutaneous (SC) risankizumab administered by on-body device (OBD) in patients with Crohn's disease (CD).</p><p><strong>Methods: </strong>Uncontrolled observational cross-sectional study in five UK units between October 2023 and May 2024. Patients who had received maintenance risankizumab <i>via</i> SC injection of four pre-filled syringes (PFS) self-administered in hospital were switched to OBD self-injection. Self-Injection Assessment Questionnaires (SIAQ) were completed pre- and post-first OBD use. The primary end-point was \"Overall, how satisfied are you with your current way of taking your medication (self-injection)?\" from post-injection SIAQ. Baseline patient data were collected retrospectively from medical records.</p><p><strong>Results: </strong>The study recruited 50 patients with moderate-to-severe CD, 48 completed the study. Most (81%) were satisfied/very satisfied with self-injection using OBD vs only 54% with PFS. Satisfaction with the OBD was highest with home use (90% vs 65%). Confidence was high with the OBD; numerically higher rates of patients were confident in giving themselves an injection in the right way (83% vs 64%), in a clean and sterile way (90% vs 74%) and safely (85% vs 72%) post-OBD than before using OBD. Self-injection using the OBD was reported as easy by 92% and convenient by 83% of participants. Most participants reported that they would continue to use the OBD (82%) and be confident to self-inject at home (81%). The OBD was well tolerated.</p><p><strong>Conclusion: </strong>The OBD provides a safe, easy to use and convenient way to self-administer risankizumab at home using one injection with improved satisfaction and confidence vs self-administration of four PFS in hospital.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"829-839"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}